post-herpetic neuralgia
Vaccines · 2014–2023
6decisions
4medicines
4carried consumer input
14individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| varicella zoster virus recombinant vaccine Prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) for non-Indigenous individuals aged 65 to 69 years and ≥71 years. | Jul 2023 | Recommended | input received |
| varicella zoster virus recombinant vaccine Prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in non-Indigenous people ≥65 years of age and Aboriginal and Torres Strait Islander people… | Mar 2023 | Recommended with restriction | 9 individuals Myeloma Australia · Immunisation Foundation · Pain Australia · Controlled Health Organisation · Australian Rheumatology Association · Multiple Sclerosis Australia · Australian Society · Pharmaceutical Society |
| recombinant varicella zoster virus glycoprotein E antigen (AS01B adjuvanted) vaccine Prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults aged 60 years and older, with a five-year catch-up program for ages 60–79 years. | Nov 2018 | Not recommended | none received |
| lignocaine Treatment of post-herpetic neuralgia (PHN), positioning as an alternative to pregabalin and gabapentin in patients with PHN refractory to other drugs. | Mar 2015 | Not recommended | 1 individuals |
| zoster virus vaccine live Prevention of herpes zoster (shingles) and post-herpetic neuralgia (PHN) in older adults aged 60 years and over. | Mar 2014 | Deferred | unclear |
| zoster virus vaccine live Prevention of herpes zoster and post-herpetic neuralgia in immunocompetent people aged 70 years (ongoing cohort) and 71-79 years (catch-up cohort). | Nov 2014 | Recommended | 4 individuals |
Who spoke
Myeloma Australia · Immunisation Foundation · Pain Australia · Controlled Health Organisation · Australian Rheumatology Association · Multiple Sclerosis Australia · Australian Society · Pharmaceutical Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.